Hydrocephalus, Normal Pressure

BOSTON, Jan. 23, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d'Isere. Data from clinical studies of the eShunt System being conducted under FDA IDE approval in the US and ANMAT approval in Argentina in patients with hydrocephalus secondary to subarachnoid hemorrhage and in patients with Normal Pressure Hydrocephalus (NPH) was presented by Dr. Ivan Lylyk (ENERI, Buenos Aires, Argentina) in an abstract entitled "Pilot Clinical Experience with the CereVasc eShunt System for the Treatment of Communicating Hydrocephalus." "We are pleased for our team to share the initial results of these thirty-one patients who have been treated with the eShunt System across multiple hydrocephalus etiologies and warrants the study of the device in a pivotal trial setting," said Dr. Pedro Lylyk, Director General of ENERI. Dan Levangie, CereVasc President & CEO stated, "We are grateful to ABC WIN for the opportunity to have Dr. Lylyk present the encouraging data from our investigators in the trials of the eShunt System. We are looking forward to leveraging the experience gained in these studies to support our pivotal study this year." About CereVasc, Inc. Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH), a potential improvement to the current standard of care. The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid (CSF) shunt and delivery components, which are designed to treat CH without invasive surgery. For additional information, please visit our website at . The eShunt® Device is an investigational device and not available for sale within or outside the United States. Company Contacts: DJ Cass CereVasc, Inc. [email protected] SOURCE CereVasc, Inc.

In certain cases, a new method can provide as much information from brain images taken with computed tomography (CT) as images captured with magnetic resonance imaging (MRI). The method could enhance diagnostic support, particularly in primary care, for conditions such as dementia and other brain disorders.  In certain cases, a new method can provide as much information from brain images taken with computed tomography (CT) as images captured with magnetic resonance imaging (MRI). The method, presented in a study from the University of Gothenburg, could enhance diagnostic support, particularly in primary care, for conditions such as dementia and other brain disorders. Computed tomography (CT) is a relatively inexpensive imaging technology that is widely available within healthcare, as well as in many parts of the world that lack access to other imaging methods. However, CT is considered inferior to magnetic resonance imaging (MRI) when it comes to reproducing subtle structural changes in the brain or flow changes in the ventricular system. Certain imaging must therefore currently be carried out by specialist departments at larger hospitals where the more advanced imaging technology is available. AI trained on MRI images The new software can provide diagnostic support for radiologists and other professionals who interpret CT images. It has been created using deep learning, a form of artificial intelligence (AI). The software has been trained to transfer interpretations from MRI images to CT images of the same brains. "Our method generates diagnostically useful data from routine CT scans that, in some cases, is as good as an MRI scan performed in specialist healthcare," says Michael Schöll, a professor at Sahlgrenska Academy who led the work involved in the study, carried out in collaboration with researchers at Karolinska Institutet, the National University of Singapore, and Lund University "The point is that this simple, quick method can provide much more information from examinations that are already carried out on a routine basis within primary care, but also in certain specialist healthcare investigations. In its initial stage, the method can support dementia diagnosis, however, it is also likely to have other applications within neuroradiology." Reliable decision-making support This is a well-validated clinical application of AI-based algorithms, and has the potential to become a fast and reliable form of decision-making support that effectively reduces the number of false negatives. The researchers believe that this solution can improve diagnostics in primary care and thus optimize patient flow to specialist care. "This is a major step forward for imaging diagnosis," says Meera Srikrishna, a postdoctor at the University of Gothenburg and lead author of the study, which has been published in the journal Alzheimer's & Dementia. "It is now possible to measure the size of different structures or regions of the brain in a similar way to advanced analysis of MRI images. The software makes it possible to segment the brain's constituent parts in the image and to measure its volume, even though the image quality is not as high with CT." Applications for other brain diseases The software has been trained on images of a total of 1,117 people, all of whom underwent both CT and MRI imaging. The current study mainly involved healthy older individuals and patients with various forms of dementia. Another application that the team is now investigating is for normal pressure hydrocephalus (NPH). With NPH, the team has obtained new results indicating that the method can be used both during diagnosis and to monitor the effects of treatment. NPH is a condition that occurs particularly in older people, whereby fluid builds up in the cerebral ventricular system and results in neurological symptoms. About two percent of all people over the age of 65 are affected. Because diagnosis can be complicated and the condition risks being confused with other diseases, many cases are likely to be missed. "NPH is difficult to diagnose, and it can also be hard to safely evaluate the effect of shunt surgery to drain the fluid in the brain," continues Michael. "We therefore believe that our method can make a big difference when caring for these patients." The software has been developed over the course of several years, and development is now continuing in cooperation with clinics in Sweden, the UK, and the US together with a company, which is a requirement for the innovation to be approved and transferred to healthcare.

BOSTON, Sept. 26, 2023 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was recently presented at the Congress of Neurological Surgeons (CNS) Annual Meeting in Washington, DC. Dr. Adel Malek, CereVasc Chief Medical Officer, presented the following at CNS: "Development of a Percutaneous Endovascular Biomimetic Shunt (eShunt) for Treatment of Communicating Hydrocephalus" "Use of the eShunt Implant in Treatment of Aneurysmal Subarachnoid Hemorrhage Communicating Hydrocephalus" "Minimally Invasive Treatment of Idiopathic Normal Pressure Hydrocephalus Using the Endovascular eShunt Implant" Dan Levangie, CereVasc President & CEO stated, "We are now seeing the impact of our eShunt System in dozens of patients treated and we are thrilled by the results, and grateful for the opportunity to share them with the physician community. The eShunt System provides the opportunity to treat both complicated conditions with a minimally invasive alternative to the current invasive standard of care. The data presented at CNS bolster our confidence in the potential of the eShunt System as we transition to broader use in a pivotal clinical trial in early 2024." About CereVasc, Inc. Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses the first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system minimally invasive treatment for communicating hydrocephalus (CH), a potential improvement to the current standard of care. The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid (CSF) shunt and delivery components, which are designed to treat CH without invasive surgery. For additional information, please visit our website at . The eShunt® Device is an investigational device and not available for sale within or outside the United States. Company Contacts: DJ Cass CereVasc, Inc. [email protected] SOURCE CereVasc, Inc.